Refine
Document Type
- Article (1)
- Part of a Book (1)
Has Fulltext
- yes (2)
Is part of the Bibliography
- no (2)
Keywords
- Brogan, John A. (1)
- Comic (1)
- Comicroman (1)
- Deutschland (1)
- King Features Syndicate (1)
- Kulturkontakt (1)
- USA (1)
Institute
- Medizin (1)
Dieser Artikel thematisiert die Anfänge und Hintergründe der Beziehung zwischen europäischer Comic-Kultur und amerikanischer Comic-Geschichte. Die erfolgreiche Etablierung amerikanischer Comics in Europa Mitte der 1930er Jahre ist eng mit den internationalen Wirtschaftsbeziehungen verbunden; verständlich wird sie aber nur, wenn man sich vor Augen führt, welchen Einfluss Engagement und Vernetzung einzelner Persönlichkeiten hatte. Es war zum Beispiel das Verdienst von John A. Brogan, Foreign Sales Manager der 1929 gegründeten internationalen Vertriebsabteilung von King Features Syndicate, dem es gelang, den europäischen Zeitungen passende Comic-Strips zum Verkauf anzubieten. Aus seinen Bemühungen resultierte in Europa die Gründung von Agenturen, die hauptsächlich dem Vertrieb von Comics gewidmet waren. Auf diese Weise wurden die organisatorischen und personellen Voraussetzungen für den transatlantischen Kulturtransfer im Bereich der Comics geschaffen.
Background: The potential anti-cancer effects of mammalian target of rapamycin (mTOR) inhibitors are being intensively studied. To date, however, few randomised clinical trials (RCT) have been performed to demonstrate anti-neoplastic effects in the pure oncology setting, and at present, no oncology endpoint-directed RCT has been reported in the high-malignancy risk population of immunosuppressed transplant recipients. Interestingly, since mTOR inhibitors have both immunosuppressive and anti-cancer effects, they have the potential to simultaneously protect against immunologic graft loss and tumour development. Therefore, we designed a prospective RCT to determine if the mTOR inhibitor sirolimus can improve hepatocellular carcinoma (HCC)-free patient survival in liver transplant (LT) recipients with a pre-transplant diagnosis of HCC. Methods: The study is an open-labelled, randomised, RCT comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing LT for HCC. Patients with a histologically confirmed HCC diagnosis are randomised into 2 groups within 4-6 weeks after LT; one arm is maintained on a centre-specific mTOR-inhibitor-free immunosuppressive protocol and the second arm is maintained on a centre-specific mTOR-inhibitor-free immunosuppressive protocol for the first 4-6 weeks, at which time sirolimus is initiated. A 3-year recruitment phase is planned with a 5-year follow-up, testing HCC-free survival as the primary endpoint. Our hypothesis is that sirolimus use in the second arm of the study will improve HCC-free survival. The study is a non-commercial investigator-initiated trial (IIT) sponsored by the University Hospital Regensburg and is endorsed by the European Liver and Intestine Transplant Association; 13 countries within Europe, Canada and Australia are participating. Discussion: If our hypothesis is correct that mTOR inhibition can reduce HCC tumour growth while simultaneously providing immunosuppression to protect the liver allograft from rejection, patients should experience less post-transplant problems with HCC recurrence, and therefore could expect a longer and better quality of life. A positive outcome will likely change the standard of posttransplant immunosuppressive care for LT patients with HCC. (trial registered at www.clinicaltrials.gov: NCT00355862) (EudraCT Number: 2005-005362-36)